Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer

Détails

ID Serval
serval:BIB_7D5E10EB0204
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer
Périodique
New England Journal of Medicine
Auteur(s)
Bernier  J., Domenge  C., Ozsahin  M., Matuszewska  K., Lefebvre  J. L., Greiner  R. H., Giralt  J., Maingon  P., Rolland  F., Bolla  M., Cognetti  F., Bourhis  J., Kirkpatrick  A., van Glabbeke  M.
ISSN
1533-4406
Statut éditorial
Publié
Date de publication
05/2004
Peer-reviewed
Oui
Volume
350
Numéro
19
Pages
1945-52
Notes
Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S. --- Old month value: May 6
Résumé
BACKGROUND: We compared concomitant cisplatin and irradiation with radiotherapy alone as adjuvant treatment for stage III or IV head and neck cancer. METHODS: After undergoing surgery with curative intent, 167 patients were randomly assigned to receive radiotherapy alone (66 Gy over a period of 6 1/2 weeks) and 167 to receive the same radiotherapy regimen combined with 100 mg of cisplatin per square meter of body-surface area on days 1, 22, and 43 of the radiotherapy regimen. RESULTS: After a median follow-up of 60 months, the rate of progression-free survival was significantly higher in the combined-therapy group than in the group given radiotherapy alone (P=0.04 by the log-rank test; hazard ratio for disease progression, 0.75; 95 percent confidence interval, 0.56 to 0.99), with 5-year Kaplan-Meier estimates of progression-free survival of 47 percent and 36 percent, respectively. The overall survival rate was also significantly higher in the combined-therapy group than in the radiotherapy group (P=0.02 by the log-rank test; hazard ratio for death, 0.70; 95 percent confidence interval, 0.52 to 0.95), with five-year Kaplan-Meier estimates of overall survival of 53 percent and 40 percent, respectively. The cumulative incidence of local or regional relapses was significantly lower in the combined-therapy group (P=0.007). The estimated five-year cumulative incidence of local or regional relapses (considering death from other causes as a competing risk) was 31 percent after radiotherapy and 18 percent after combined therapy. Severe (grade 3 or higher) adverse effects were more frequent after combined therapy (41 percent) than after radiotherapy (21 percent, P=0.001); the types of severe mucosal adverse effects were similar in the two groups, as was the incidence of late adverse effects. CONCLUSIONS: Postoperative concurrent administration of high-dose cisplatin with radiotherapy is more efficacious than radiotherapy alone in patients with locally advanced head and neck cancer and does not cause an undue number of late complications.
Mots-clé
Adolescent Adult Aged Antineoplastic Agents/adverse effects/*therapeutic use Carcinoma, Squamous Cell/*drug therapy/mortality/*radiotherapy/surgery Cisplatin/adverse effects/*therapeutic use Combined Modality Therapy/adverse effects Disease-Free Survival Female Follow-Up Studies Head and Neck Neoplasms/*drug therapy/mortality/*radiotherapy/surgery Humans Male Middle Aged Radiotherapy/adverse effects Risk Survival Rate
Pubmed
Web of science
Création de la notice
24/01/2008 18:16
Dernière modification de la notice
03/03/2018 18:39
Données d'usage